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Recent guidelines on cancer screening have provided not only more screening options but also conflicting recommendations.
Thus, patients, with their clinicians’ support, must decide whether to get screened, which modality to use, and how often to
undergo screening. Decision aids could potentially lead to better shared decision-making regarding screening between the
patient and the clinician. A total of 73 decision aids concerning screening for breast, cervical, colorectal, and prostate cancers
were reviewed. The goal of this review was to assess the effectiveness of such decision aids, examine areas in need of more
research, and determine how the decision aids can be currently applied in the real-world setting. Most studies used sound study
designs. Significant variation existed in the setting, theoretical framework, and measured outcomes. Just over one-third of the
decision aids included an explicit values clarification. Other than knowledge, little consistency was noted with regard to which
patient attributes were measured as outcomes. Few studies actually measured shared decision-making. Little information was
available regarding the feasibility and outcomes of integrating decision aids into practice. In this review, the implications for
future research, as well as what clinicians can do now to incorporate decision aids into their practice, are discussed.
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Introduction
In recent years, screening strategies for many conditions have become increasingly complex. Guidelines now recommend
more options for cancer screening. Some guidelines also have conflicting recommendations. Thus, patients, with their
clinicians’ support, must decide whether to get screened, which modality to choose, and how often to undergo screening.
These considerations are foundational to informing patients’ preferences, and make these decisions ‘‘preference-sensitive.’’
Decision aids could be an ideal tool to help patients understand their risk of developing a particular cancer, the screening
options available (including the possible option of not getting screened), recommended screening time intervals, and their
own values and preferences for a particular option and outcome. Consequently, decision aids have proliferated in recent
years. They usually include information on the disease/condition and the associated tests/treatments, probabilities of
outcomes (benefits and harms) for each test/treatment option, and some form of a values clarification exercise to help
patients determine which option would best match their values. Decision aids may also include guidance or coaching in the
process of decision-making.1 They are not meant to replace the discussion between the patient and his/her clinician, but
rather to complement it.
Cancer screening decisions are increasingly recognized as being preference-sensitive, due to the increased recognition of
harms from sequelae of screening, the need to tailor screening recommendations to the patient’s risk, the multiple options
available in some screening tests, and conflicting recommendations from guidelines. The potential of harm from screening
was highlighted recently when the US Preventive Services Task Force recommended against routine screening for prostate
cancer.2 They made this recommendation while other guidelines had similarly weighed the benefits and harms of prostate
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cancer screening and instead of discouraging screening,
stressed shared decision-making between the patient
and the clinician to decide whether the patient should
undergo screening.3 Other cancer screenings involve
preference-sensitive decisions as well, such as colorectal
cancer screening, in which options include stool blood
testing, flexible sigmoidoscopy, colonoscopy, and other
modalities.4,5 Even screening for cancers that traditionally
are without many options has become more complex, with
some recent guidelines recommending shared decision-
making between the patient and clinician to determine
whether to get screened for breast cancer among women
aged 40 years to 49 years,6 consideration of magnetic
resonance imaging for women with a high risk of breast
cancer,7 and the option of cytological testing every 3 years
or cytological testing plus human papillomavirus testing
every 5 years to screen for cervical cancer.8 The purpose of
this review is to summarize what is known about the effect
of decision aids on cancer screening, and to explore areas
in which more information is needed to fully understand
the impact of decision aids on the process and outcomes
of shared decision-making between the patient and
the clinician.
Materials and Methods
Screened Cancers
We focused our attention on cancers for which the national
guidelines recommend screening the general population.4-8
Thus, we selected the decision aids for the screening of
breast, cervical, and colorectal cancers. In addition, we
looked at genetic testing for women considered to be at
high risk of breast cancer, since it was believed to be an
important option for selected high-risk women desiring
further screening evaluation for breast cancer. Finally, we
included prostate cancer screening in our search, since
all guidelines except those by the US Preventive Services
Task Force recommend that at least a discussion occur
between the patient and clinician to decide whether
screening for prostate cancer would be warranted in the
particular patient.2,3
Study Identification
The literature search was conducted for English language
articles in 5 databases: MEDLINE (January 1980-May
2012), Cumulative Index to Nursing and Allied Health
Literature (CINAHL; January 1980-May 2012),
EMBASE (1980-May 2012), Cochrane Central Register
of Controlled Trials (CCRCT; updated May 2012), and
Science Citation Index (SCI; January 1980-May 2012).
The MEDLINE, CINAHL, EMBASE, and CCRCT
searches were conducted via the Ovid Technologies Inc
interface. The majority of the topical search retrieval was
obtained via MEDLINE using Medical Subject Headings,
including ‘‘breast neoplasms;’’ ‘‘colorectal neoplasms;’’
‘‘uterine cervical neoplasms;’’ ‘‘prostatic neoplasms;’’ ‘‘mass
screening;’’ ‘‘decision support techniques;’’ ‘‘decision-
making;’’ ‘‘decision-making, computer-assisted;’’ and
‘‘decision support systems, clinical.’’ In addition, limited text
word searching was used. Corresponding keyword searches
with Boolean syntax were conducted in CCRCT and SCI.
Theoretical Framework
In order to provide a theoretical organizing framework for
our evaluation of studies, we have adapted the Integrative
Model of Behavior by Frosch et al, which combines the
4 theories most frequently applied in health behavior
research within the past 30 years (Theory of Reasoned
Action, Theory of Planned Behavior, Health Belief Model,
and Social Cognitive Theory).9 This theory combines
measurable constructs of behavior (attitudes, perceived
social norms, self-efficacy, and behavioral intention) to
the actual behavior. Because an important aspect of
decision aids is the clarification of preferences and values,
we have added that component, as well as how the
subsequent patient/clinician discussion ensues in terms of
shared decision-making and patient/clinician concordance
(match between the patient’s preferred screening option
and the clinician’s recommended option).10,11 Figure 1
illustrates our adapted framework with relevant examples.
Applied to the topic of this review, the use of decision aids
to affect the patient’s behavior regarding cancer screening,
this theoretical framework provides a helpful structure for
understanding where decision aids intervene and exert their
influence on screening behavior. It influenced the selection
of the decision attributes evaluated. Our analysis focused
on understanding the impact of the decision aid on
patient’s attributes, shared decision-making, and patient/
clinician concordance. Our model suggests that all of these
are important to understanding the impact on patient
screening behavior and determined the questions posed in
the review.
Procedure
Two evaluators (M.J. and M.R.) reviewed each of the
identified articles independently to determine if the study
was relevant to the topic. Publications were excluded if the
article was a review; an opinion article; an abstract;
descriptive of a new decision aid without an intervention/
trial component; or measured for usability but not for
effects on patient knowledge, attitude, or behavior. Articles
also were excluded if the study patients had an established
cancer diagnosis, since our focus was on cancer screening.
For the same reason, we excluded the study if it included
treatment (eg, prophylactic mastectomy) as an option.
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We selected the studies if the decision aid contained
information on the disease/condition and the associated
tests/treatments and probabilities of outcomes (benefits
and harms) for each test/treatment option.1 We excluded
studies in which the intervention was provided solely
through a health care professional (eg, a script) since
decision aids by definition are separate tools that
complement the patient/clinician discussion and aid in
decision-making. We did not directly contact the study
authors but thoroughly reviewed the relevant articles for
the original and detailed description of the decision aid
intervention and, when necessary, reviewed the references
for the original description of the intervention. We also
directly accessed the decision aids if available. We included
preintervention/postintervention and other nonrandomized
designs as well as randomized controlled designs because
we wanted to be as inclusive as possible to capture
innovative decision aids. For that reason, we also included
pilot studies as long as they had intervention and evaluation
components. A number of publications were found that
were duplicate reports of a single study or serial reports
from the same study. In these cases, the study was counted
as one, although all pertinent publications were reviewed.
The cited literature referenced in relevant studies was also
examined for possible additional studies.
Study Questions/Measures
We categorized the measures into the following questions.
1) Does the Decision Aid Used in the Study Address
the Issues That Need to Be Addressed in a Screening
Decision Aid?1
We determined whether the decision aid included
information on the cancer and the screening test options
involved, probabilities of outcomes including the benefits
and harms for each option, an explicit value clarifications
exercise to help the patient determine which option would
best match his/her values, and guidance or coaching in
the process of decision-making. For values clarification,
we specifically looked for the existence of a process (eg,
exercise) that would actively engage the patient in clarifying
his/her values. For guidance or coaching, we examined the
specific ways in which the decision aid or the study
addressed the discussion with the clinician.
2) Does the Study Measure the Effect of the Decision
Aid on the Patient Attributes Established in the
Theories of Behavioral Research?
We determined whether the study measured the patient’s
knowledge, attitude, perceived normative pressure, self-
efficacy, preference clarification, and intent regarding the
cancer and cancer screening test in question. Here,
preference is different from values in that ‘‘preference’’ is
defined as an actual preference for a certain option.
3) Does the Study Address the Impact of the Decision
Aid on the Patient Behavior in Question?
We determined whether the decision aid increased or
decreased patient uptake of the particular cancer screening
test, and whether it was by subjective (eg, patient
self-report) or objective (eg, chart review) report. We also
determined whether the completed cancer screening test
was the option that the patient had originally chosen at the
time of the decision aid use.
4) Does the Study Address the Effect of the Decision
Aid on the Subsequent Discussion Between the Patient
and His/Her Clinician?
We determined whether the study addressed the
subsequent discussion between the patient and his/her
clinician (ie, shared decision-making) and whether it was
affected by use of the decision aid. We also determined
FIGURE 1. Adaptation of the Integrative Model of Behavior Using the Example of a Decision Aid on Colorectal Cancer (CRC) Screening.
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whether there was concordance between the patient and
the clinician (ie, whether they agreed on a particular cancer
screening test option).11 In addition, we determined
whether any other factors after the patient/clinician
encounter (eg, family members, media) were considered as
having influenced the patient’s screening behavior.
5) Does the Decision Aid Appear to Be Applicable
in Real-World Practice?
We determined the feasibility of applying the decision aid
in real-world practice through the study’s setting and
patient selection, and whether the decision aid was stand-
alone or done in conjunction with other clinical activities.
We also determined whether the study addressed the
ability of the decision aid to be used in repeat screening and
whether cost analysis was performed.
Determination of Outcomes
For the outcomes, only those outcomes based on intention
to treat were considered when the intention-to-treat
numbers were available. In addition, when the P value was
available, only those outcomes that were statistically
significant at P< .05 were considered to be meaningfully
different. Outcomes were compared between groups for
the studies that were randomized or factorial in design.
Outcomes were compared before and after the intervention
for those studies with a preintervention/postintervention
design.
Specific Areas Addressed Based on the
5 Questions
The 2 evaluators independently read each publication to
determine each of the following areas: 1) primary author
and year; 2) target cancer for screening; 3) cancer screening
options addressed; 4) target population and characteristics
(eg, patient, clinician, or both); 5) study design; 6) setting
(eg, community or academic); 7) follow-up duration;
8) content of the decision aid (theoretical framework,
provision of information, risks and benefits, values
clarification exercise, guidance on decision-making and
communication, provision of a no-screening option, and
discussion of when to stop screening); 9) patient outcomes
assessed for the decision aid (knowledge, attitude,
subjective norm, self-efficacy, preference clarification,
intention, and screening behavior) as well as whether it was
a self-report or an observational review; 10) patient/
clinician outcomes assessed for the decision aid (shared
decision-making and concordance); and 11) practice
outcomes assessed for the decision aid (postvisit factors [eg,
effect of media, family, and friends], incorporation of the
decision aid into practice [eg, meaningful use], effect of the
decision aid on repeated screening, and cost analysis).
The evaluators met as a group to review their
classifications, discussed any disagreements, and arrived at a
consensus of opinion for all studies.
Results
Seventy-nine studies were identified that evaluated 73
decision aids meeting the criteria outlined above. Only 2
decision aids dealt with cervical cancer screening.12,13
Eighteen decision aids dealt with breast cancer screening, 9
of which concerned mammography for the general
population14-23 and 9 of which concerned genetic testing
for those considered to be at high risk of breast cancer
based on family history and other information.24-33
Twenty-one decision aids dealt with colorectal cancer
screening34-54; 29 dealt with prostate cancer screening55-87;
2 decision aids dealt with both colorectal and prostate
cancer screening88,89; and one decision aid dealt with
all 4 cancer screenings: breast, cervical, colorectal,
and prostate.90
Characteristics of the Identified Studies
Table 112-90 summarizes the characteristics of the
identified studies. For breast and prostate cancer screening,
options were a single test, namely mammography14-23 or
genetic testing (BRCA)24-33 and prostate-specific
antigen,55-87 respectively. The breast self-examination and
clinical breast examination in one decision aid on
mammography screening were not considered options but
rather came as a set with the mammogram.14 Similarly,
digital rectal examination and prostate-specific antigen
testing in 12 of the 29 decision aids on prostate cancer
screening were not options but were considered as a
set.58,59,61,65,69,73,75,77-79,82,87 The 2 decision aids on
cervical cancer screening also dealt with a single test:
cervical cytology (Papanicolaou test).12,13 Decision aids for
colorectal cancer screening were the only ones that
considered choosing among multiple screening test options.
In these cases, the options varied from just one (4 of 21
decision aids)37,45,47,49 to 2 (4 decision aids)39,43,48,53 to 3
or more (13 decision aids).34-36,38,40-42,44,46,50-52,54 One
study explicitly compared a 2-option decision aid, namely
stool blood test and colonoscopy, with a 5-option decision
aid with options that included stool blood test, flexible
sigmoidoscopy, stool blood test and flexible sigmoidoscopy,
barium enema, and colonoscopy.41 Of note, the newer
screening tests of magnetic resonance imaging for women
at high risk of breast cancer, human papillomavirus testing
for cervical cancer screening, and computed tomography
colonography and stool DNA testing for colorectal cancer
screening have not yet been incorporated into the published
decision aids.
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TABLE 1. Characteristics of Identified Studies on Decision Aids
STUDYa SCREENING OPTIONS TARGET POPULATIONb DESIGN SETTING
FOLLOW-UP
DURATION
Breast cancer mammography screening (n¼9)
Kadison 199814 BSE, CBE, MMG Women aged 22-75 y Longitudinal uncontrolled study:
interactive voice-response risk
assessment (initially: n¼343;
follow-up: n¼189)
2 companies in United States 8 mo
Street 199815 MMG Women aged 40-75 y RCT: computer-based multimedia
DA (n¼54) vs print DA (n¼54)
2 primary care clinics in
United States
Immediate
Lawrence 200016 MMG Women aged 49-89 y One-time uncontrolled intervention:
print DA (n¼103)
One medical school, one
primary care clinic, and
one community center
in United States
Immediate
Valdez 200117 MMG Hispanic women aged 40 y Parallel-group randomized experimental
design (pre vs post): computer
kiosk-based DA (n¼269)
5 clinics and one
community-based
organization
in United States
4 mo
Rimer 200118 and
Rimer 200219
MMG Women aged 40-44 y and 50-54 y 3-arm RCT: tailored print newsletter
plus telephone counseling (n¼339)
plus tailored print newsletter (n¼374)
plus usual care (n¼378)
One state-based health
insurance membership
in United States
24 mo
Lewis 200320 MMG Women aged 35-49 y 3-arm RCT: positive video (n¼64) vs
neutral video (n¼54) vs negative
video (n¼60)
University-based general
medicine clinic in
United States
Immediate
Mathieu 200721 MMG Women aged 70-71 y RCT: print DA (n¼367) vs usual
care (n¼367)
Communities in Australia 1 mo
Vernon 200822 MMG Women aged 52 y 3-arm RCT: tailored print plus
targeted print intervention (n¼1803)
plus targeted print intervention only
(n¼1857) plus usual care (n¼1840)
National veteran registry
in United States
2 y
Mathieu 201023 MMG Women aged 38-45 y RCT: immediate Web-based DA (n¼189)
vs delayed Web-based DA (n¼223)
Online recruitment in
Australia
Immediate
Breast cancer genetic testing (n¼9)
Lerman 199724 BRCA testing Women aged 18-75 y with family
history of breast or ovarian cancer
3-arm RCT: print DA plus counseling
(n¼122) plus print DA (n¼114) only vs
waiting list control (n¼164)
2 cancer centers in
United States
1 mo
Green 200125 BRCA testing Women aged 19-59 y with
family history of breast cancer
3-arm RCT: interactive, multimedia CD-ROM
DA plus counseling (n¼29) vs counseling
(n¼29) vs usual care (n¼14)
One federal research
facility in United States
Immediate
Schwartz 200126 BRCA testing Ashkenazi Jewish women
aged 18-83 y
RCT: print DA (n¼191) vs usual
care (n¼190)
Religious organization
in United States
1 mo
Green 200427 and
Green 200528
BRCA testing Women aged 24-77 y with personal
or family history of breast cancer
RCT: interactive, multimedia CD-ROM DA
plus counseling (n¼106) vs counseling
alone (n¼105)
5 university hospitals and
one community hospital
in United States
6 mo
Miller 200529 BRCA testing Women aged 18 y RCT: print DA vs usual care
(total n¼279)
One federal research facility
in United States
6 mo
Wang 200530 BRCA testing Women aged 22-76 y 22 factorial design: CD-ROM DA
plus counselor feedback (n¼50) vs
CD-ROM DA only (n¼50) vs counselor
feedback only (n¼49) vs usual
care (n¼48)
One university-based cancer
clinic in United States
Immediate
Wakefield 200831 BRCA testing Women aged 18 y with family
history of breast/ovarian cancer
RCT: print DA (n¼73) vs control
pamphlet (n¼72)
5 cancer clinics in Australia 6 mo
Wakefield 200832 BRCA testing Women aged 18 y with family
history of breast/ovarian cancer
RCT: detailed print DA (n¼73) vs
control pamphlet (n¼75)
5 cancer clinics in Australia 6 mo
Gray 200933 BRCA testing Women aged 18-70 y with personal/
family history of breast or
ovarian cancer
3-arm RCT: Web site with risk information
on BRCA testing attributed to experts
(n¼98) vs not attributed (n¼93) vs
no risk information (n¼93)
1 university-based research
facility in United States
Immediate
Cervical cancer screening (n¼2)
Adab 200312 Cervical cytology Women aged 20-64 y RCT: leaflet with risks and
uncertainties (n¼155) vs
standard leaflet (n¼145)
3 general practices in
United Kingdom
Immediate
Park 200513 Cervical cytology Women of unknown ages Nonequivalent, control group,
posttest only design: DA (n¼48) vs
usual care (n¼48)
One church in Korea Immediate
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TABLE 1. (Continued)
STUDYa SCREENING OPTIONS TARGET POPULATIONb DESIGN SETTING
FOLLOW-UP
DURATION
Colorectal cancer screening (n¼21)
Pignone 200034 SBT, FS, SBT plus FS Men and women aged 50-75 y RCT: video DA (n¼125) vs
usual care (n¼124)
3 community primary care
practices in United States
3-6 mo
Wolf & Schorling 200035 SBT, FS, SBT plus FS Men and women 65 y 3-arm RCT: absolute risk script
(n¼136) vs relative risk script
(n¼130) vs control script (n¼133)
4 general internal medicine
practices (one university
and 3 community) in
United States
Immediate
Dolan & Frisina 200236 SBT, FS, SBT plus
FS, BE, COL
Men and women aged 50-83 y RCT: print DA (n¼50) vs usual care (n¼47) One community and one
university-based internal
medicine clinc in United States
Immediate
Zapka 200437 FS Men and women aged 50-74 y RCT: educational video (n¼450) plus
mailing vs no video (n¼488)
5 primary care practices
in United States
6 mo
Jerant 200738 SBT, FS, COL Men and women aged 50 y RCT: tailored multimedia computer program
(n¼24) vs nontailored program (n¼25)
6 community family practices
in United States
Immediate
Myers 200739 SBT, SBT plus FS Men and women aged 50-74 y 4-arm RCT: tailored print plus telephone
counseling (n¼386) vs tailored
print (n¼386) vs nontailored print
(n¼387) vs usual care (n¼387)
One university-based family
practice in United States
24 mo
Ruffin 200740 SBT, FS, SBT plus
FS, BE, COL
Men and women aged 50-70 y
who were never screened for CRC
RCT: Interactive Web site (n¼87) vs
standard Web site (n¼87)
3 communities (urban,
suburban, and rural)
in United States
24 wk
Griffith 200841 SBT, FS, SBT plus FS,
BE, COL (SBT,
COL in 2-option)
Men and women aged 48-75 y RCT: 5-option DVD DA (n¼25) vs
2-option DVD DA (n¼37)
One university-based
research facility in
United States
Immediate
Griffith 200842 SBT, FS, SBT plus
FS, BE, COL
Men and women aged 50-85 y RCT: 5-option plus no-screening
option video DA (n¼57) vs
5-option video DA (n¼49)
3 communities in
United States
Immediate
Katsumura 200843 SBT, COL Men and women aged 40-59 y RCT: Internet-based information
plus risk information (n¼146)
vs Internet-based information
only (n¼139)
1 Internet community in Japan Immediate
Lewis 200844 SBT, FS, COL Men and women aged 50-75 y RCT: mailed print DA (n¼137)
plus waiting list control (n¼100)
University-based general
medicine clinic in
United States
5 mo
Trevena 200845 SBT Men and women aged 50-74 y RCT print DA (n¼157) vs government
guidelines (n¼157)
6 community family
practices in Australia
1 mo
Makoul 200946 SBT, FS, COL Hispanic men and women
aged 50-80 y
Pretest/posttest design: computer kiosk
DA (n¼270)
2 community clinics in
United States
Immediate
Manne 200947 COL Men and women with family
history of CRC
3-arm RCT: tailored print plus
telephone counseling (n¼112) vs
tailored print (n¼161) vs standard
print (n¼139)
26 medical centers in
United States
6 mo
Lewis 201048 SBT, COL Men and women aged 75-95 y One-time uncontrolled intervention:
print DA (n¼46)
One senior center in
United States
Immediate
Smith 201049 SBT Men and women with low
educational attainment,
aged 55-64 y
3-arm RCT: print and DVD DA plus
question prompt list (n¼196) vs
print and DVD DA only (n¼188) vs
standard information (n¼188)
Community in Australia 3 mo
Miller 201150 SBT, FS, COL Men and women aged 50-74 y RCT: Web-based DA (n¼132)
vs usual care (n¼132)
One community internal
medicine clinic in United States
24 wk
Pignone 201151 SBT, FS, SBT plus
FS, BE, COL
Men and women aged 52-80 y Clustered RCT: DVD/VHS DA (n¼211)
plus academic detailing of practices
vs usual care (n¼232)
32 primary care practices
participating in a single
health insurance plan
in United States
12 mo
Schroy 201152 SBT, FS, SBT plus
FS, BE, COL
Men and women aged 50-75 y 3-arm RCT: DVD DA plus personalized
risk assessment (n¼223) vs DVD
DA (n¼212) vs usual care (n¼231)
One university-based internal
medicine clinic and one
community health center
in United States
Immediate
Steckelberg 201153 SBT, COL Men and women aged 50-75 y RCT: print DA with risk information
(n¼785) vs print standard information
(n¼792)
Health insurance membership
in Germany
6 mo
Vernon 201154 SBT, FS, BE, COL Men and women aged 50-70 y 3-arm RCT: tailored Web site (n¼413) vs
nontailored Web site (n¼398) vs
usual care (n¼413)
One university-based clinic
in United States
24 mo
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TABLE 1. (Continued)
STUDYa SCREENING OPTIONS TARGET POPULATIONb DESIGN SETTING
FOLLOW-UP
DURATION
Prostate cancer screening (n¼29)
Flood 199655 PSA Men aged 50 y RCT: educational videotape (n¼184) vs
control videotape (n¼188)
One university hospital in
United States (free
screening program and clinic)
Immediate
Wolf 199656 and
Wolf & Schorling 199857
PSA Men aged 50 y RCT: scripted DA (n¼103) vs usual
care (n¼102)
4 university-affiliated primary
care practices in United States
Immediate
Myers 199958 PSA, DRE Men aged 40-70 y RCT: print information plus tailored
information (n¼192) vs print
information only (n¼221)
One university-based clinic
in United States
1 y
Schapira & Van Ruiswyk
200059
PSA, DRE Men aged 50-80 y RCT: print DA with detailed risk
description (n¼122) vs print information
without (n¼135)
One Veterans Administration
clinic in United States
2 wk
Frosch 200160 PSA Men aged 50 y 22 factorial design: shared decision-making
video plus discussion on risks and benefits
(n¼42) vs video only (n¼46) vs discussion
only (n¼45) vs usual care (n¼43)
One community hospital
in United States
Immediate
Wilt 200161 PSA, DRE Men aged 50 y RCT: mailed print DA (n¼180) plus
survey vs usual care (n¼195)
One Veterans Administration
primary care clinic in
United States
1 y
Volk 199962 and Volk 200363 PSA Men aged 45-70 y RCT: video DA before physician visit
(n¼80) vs information booklet 2 wk
after physician visit (n¼80)
One university-based family
medicine clinic
1 y
Frosch 200364 PSA Men aged 50 y RCT: Web-based DA (n¼114) vs
video DA (n¼112)
One community hospital
in United States
Immediate
Gattellari & Ward 200365 PSA, DRE Men aged 40-70 y RCT: print DA (n¼126) vs conventional
pamphlet (n¼122)
13 general practices in Australia 3 d
Ruthman & Ferrans 200466 PSA Men aged 50-80 y Staged 2-group pretest/posttest
quasi-experimental design: video
DA (n¼52) vs usual care (n¼52)
One Veterans Administration
clinic in United States
Immediate
Sheridan 200467 PSA Men aged 45-85 y One-time uncontrolled intervention with
pretest/posttests: print DA (n¼188)
One university-based internal
medicine clinic in United States
Immediate
Gattellari & Ward 200568 PSA Men aged 50-70 y 3-arm RCT: video DA (n¼141) vs print
DA (n¼140) vs conventional
leaflet (n¼140)
One large community in Australia 7 d
Myers 200569 PSA, DRE African American men
aged 40-69 y
RCT: print DA plus educational session
(n¼121) vs print DA only (n¼121)
3 community primary care
practices in United States
6-11 mo
Partin 200470 and
Partin 200671
PSA Men aged 50 y 3-arm RCT: video DA (n¼308) vs print DA
(n¼295) vs usual care (n¼290)
4 Veterans Administration
clinics in United States
1 y
Watson 200672 PSA Men aged 40-75 y RCT: print DA plus survey (n¼980) vs
usual care (n¼980)
11 general practices in
United Kingdom
Immediate
Kripalani 200773 PSA, DRE Men aged 45-70 y 3-arm RCT: detailed educational print
(n¼101) vs simple educational print
(n¼101) vs usual care (n¼101)
One academic teaching
hospital in United States
Immediate
Krist 200774 PSA Men aged 50-70 y 3-arm RCT: Web-based DA (n¼226) vs
print DA (n¼196) vs usual care (n¼76)
One community family
practice in United States
2 wk
Ellison 200875 PSA, DRE African American men
aged 40-65 y
RCT: Web-based DA tailored to family
history of prostate cancer (n¼46) vs
Web-based nontailored DA (n¼41)
One annual Mason convention
in United States
Immediate
Ilic 200876 PSA Men never screened for prostate
cancer, aged >45 y
3-arm RCT: Web-based education (n¼56) vs
video-based education (n¼55) vs print-
based education (n¼50)
5 states in Australia 1 wk
Stephens 200877 PSA, DRE African American men aged
40-70 y and non-African
American men
aged 50-70 y
Solomon 4-group design: pretest plus print
DA plus post-DA process measures plus
posttest (n¼50) vs DA booklet plus
post-DA process measures plus
posttest (n¼50) vs pretest plus
posttest (n¼50) vs posttest only (n¼50)
10 urban professional research
facilities in United States
Immediate
Volk 200878 PSA, DRE African American men aged
40-70 y, non-African American
men aged 50-70 y
RCT: computer-based interactive DA
(n¼224) vs print DA plus CD (n¼226)
2 primary care clinics in
United States
2 wk
Weinrich 200879 PSA, DRE African American men aged
40-70 y, white men aged
50-70 y
Postintervention, quasi-experimental
design: enhanced DA (print DA plus
physician and peer pictures and
statements; n¼120) vs print DA
only (n¼110)
4 urban communities in
United States
Immediate
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Content of Decision Aids
Tables 2 summarizes the content of the decision aids used in
the studies.12-90 Most decision aids used a theoretical frame-
work (41 of 73 decision aids), particularly the transtheoretical
model (11 decision aids)15,18,19,22,34,38,41,42,47,50,51,54 and
the Ottawa Decision Support Framework (8 decision
aids).21,23,31,32,48,52,82,83 Interestingly, most decision aids on pro-
state cancer screening (19 of 29 decision aids)55-57,60-68,72-78,84-86
and all decision aids on multiple cancer screening (n¼3)89,90
did not incorporate a theoretical framework. A few had
adopted a formative approach (eg, interviews, focus
groups, and expert feedback; 24 of 73 decision
aids),16,17,22,29,31,32,34,36,40,42,44,46,48,52,53,55,59,60,62,63,70,71,83,88,89
but others seemed to have moved relatively quickly from
literature and expert review to the creation of the tool
and pretesting.
Variation was seen in the methods of values clarification, in
which the patient actively engages in a process where his or
her values regarding the screening test(s) are clarified. The
patient had to be actively involved in such an exercise, such as
writing out the pros and cons (in cases of paper-based
decision aids) or clicking on choices (in the case of Web-based
and other interactive decision aids). Fewer than one-half of
the decision aids used these exercises (27 of 73 decision
aids).18,19,21-23,25,27,28,31,32,36,38-40,43,45,48,49,52,54,58,65,68,69,78,80-84
Neither of the 2 decision aids that addressed cervical cancer
screening12,13 nor any of the 3 decision aids that addressed
multiple cancer screenings88-90 incorporated them.
Variation was also seen in the methods of providing
guidance for making decisions and communicating with the
clinician. Some were simply a statement of recommendation
to speak to a clinician.14,18,19,21,36,40,46,52,55,58,62-64,66,70-73,77
TABLE 1. (Continued)
STUDYa SCREENING OPTIONS TARGET POPULATIONb DESIGN SETTING
FOLLOW-UP
DURATION
Frosch 200880 and
Bhatnagar 200981
PSA Men aged 50 y 22 factorial design: didactic DA plus
chronic disease trajectory (n¼152) vs
DA only (n¼155) vs chronic disease
trajectory only (n¼153) vs control
(public Web sites on prostate
cancer; n¼151)
One community hospital in
United States
2-3 wk
Allen 200982 PSA, DRE African American men 50 y Pretest/posttest quasi-experimental design:
computerized-tailored DA (n¼108)
Multiple community settings in
United States
Immediate
Allen 201083 PSA Men aged 45 years RCT: computerized-tailored DA (n¼398) vs
no intervention (n¼414)
12 work sites in United States 3 mo
Joseph-Williams 201084 PSA Men never screened with PSA,
aged 50-75 y
4-arm RCT: Web-based DA (n¼129) vs
print DA (n¼126) vs surveys only
(n¼127) vs usual care (n¼132)
One community in
United Kingdom
6 mo
Rubel 201085 PSA Non-African American men aged 50-70 y Solomon 4-group design: pretest plus
print DA plus posttest (n¼50) vs
print DA plus posttest (n¼50) vs
pretest plus posttest (n¼50) vs
posttest only (n¼50)
5 professional research facilities
in United States
Immediate
van Vugt 201086 PSA Men aged 55-65 y never screened
with PSA
One-time uncontrolled intervention
with pretests/posttests: print
DA (n¼729)
One city in the Netherlands Immediate
Capik & Gozum 201287 PSA, DRE Turkish men aged 41-65 y Pretest/posttest longitudinal study:
Web-assisted education and
reminders (n¼110)
2 public institutions in Turkey 6 mo
Multiple cancer screening (n¼3)
Frosch 200888 Prostate: PSA;
colorectal: not specified
Men and women aged 50 y
except African American men,
who were aged 45 y
Sequential distribution of information
brochure and video DA: video DA
(n¼100) vs information brochure
(n¼107)
13 community-based primary
care practices in United States
Immediate
Brackett 201089 Prostate: PSA;
colorectal: not specified
Men aged 50-75 y for prostate cancer;
men and women aged 50-75
years for CRC
4 video DA distribution methods:
automatic previsit DA mailing
(n¼1625), previsit video DA
mailing on request (n¼84),
postvisit video DA offered by
medical assistant (n¼724), postvisit
video DA offered by physician (n¼52)
One rural university hospital and one
rural Veterans Administration
hospital in United States
Immediate
Krist 201290 Prostate: PSA; breast,
cervical, colorectal:
not specified
Men and women aged 18-75 y RCT: interactive preventive health
record that includes DAs pertinent
to the patient’s indicated cancer
screening (n¼2250) vs usual care
(n¼2250)
8 primary care practices in
United States
16 mo
BSE, breast self-examination; CBE, clinical breast examination; MMG, mammography; RCT, randomized controlled trial; DA, decision aid; SBT, stool blood test;
FS, flexible sigmoidoscopy; BE, barium enema; COL, colonoscopy; CRC, colorectal cancer; PSA, prostate-specific antigen; DRE, digital rectal examination.
aListed in ascending order by the year of publication for each cancer.
bAll target populations were patients, not clinicians.
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TABLE 2. Content of Decision Aids
STUDYa
THEORETICAL
FRAMEWORK
DESCRIPTION OF
DEVELOPMENT
PROVISION OF
INFORMATION
RISKS AND
BENEFITS
VALUES
CLARIFICATION
EXERCISE
GUIDANCE ON
DECISION-MAKING
AND
COMMUNICATION
ADDRESSES
OPTION
OF NO
SCREENING
ADDRESSES
WHEN TO
STOP
SCREENING
Breast cancer mammography screening (n¼9)
Kadison 199814 None Literature review, peer-review,
pretest
Yes No No Yes No No
Street 199815 Transtheoretical model,
elaboration
likelihood model
Pilot test Yes No No No No No
Lawrence 200016 None Content development by
multidisciplinary
team and lay women;
reliability
and validity testing
Yes Yes No No No No
Valdez 200117 Social learning theory Expert consultation,
key informant
interviews, focus groups
Yes No No Yes No No
Rimer 200118 and
Rimer 200219
Transtheoretical model,
precaution adoption
process model
Tailored messages based
on baseline
survey findings
Yes Yes Yes Yes Yes No
Lewis 200320 None Literature review, pretest Yes Yes No No Yes No
Mathieu 200721 Ottawa Decision
Support Framework
Markov model, pilot test Yes Yes Yes Yes Yes Yes
Vernon 200822 Transtheoretical model,
Health Belief Model,
Social Cognitive
Theory, Theory
of Planned Behavior
Targeted: focus
groups Tailored:
tailored messages based
on baseline survey findings
Yes Yes Yes Yes No No
Mathieu 201023 Ottawa Decision
Support Framework
Markov model, pilot test Yes Yes Yes Yes Yes No
Breast cancer genetic testing (n¼9)
Lerman 199724 Behavioral models of
decision-making
Structural protocol Yes Yes No No Yes No
Green 200125 None Provides same information as
the genetic counselors
Yes Yes Yes Yes Yes No
Schwartz 200126 None NA Yes Yes No No Yes No
Green 200427 and
Green 200528
None Provides same information as
the genetic counselors
Yes Yes Yes No Yes No
Miller 200529 Cognitive-social health
processing model
Formative evaluation:
interviews, focus groups
Yes Yes No Yes Yes No
Wang 200530 None Collaboration between content
experts and health-related
media experts
Yes Yes No Yes Yes No
Wakefield 200831 Ottawa Decision
Support Framework
Content analysis, pilot test Yes Yes Yes Yes Yes No
Wakefield 200832 Ottawa Decision
Support Framework
Content analysis, pilot test Yes Yes Yes Yes Yes No
Gray 200933 Social Cognitive
Theory
Literature review,
expert consultation,
pretest
Yes Yes No No Yes No
Cervical cancer screening (n¼2)
Adab 200312 None Added information
on risks and
uncertainties to the National
Health Service Cervical
Screening Programme leaflet
Yes Yes No No No No
Park 200513 Health Belief Model,
Theory of Reasoned
Action, self-efficacy
theory
Developed from focus groups Yes Yes No No No No
Colorectal cancer screening (n¼21)
Pignone 200034 Transtheoretical model Patient preference checking,
focus groups
Yes Yes No Yes No No
Wolf & Schorling 200035 None Physician panel, pilot testing Yes Yes No No Yes No
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TABLE 2. (Continued)
STUDYa
THEORETICAL
FRAMEWORK
DESCRIPTION OF
DEVELOPMENT
PROVISION OF
INFORMATION
RISKS AND
BENEFITS
VALUES
CLARIFICATION
EXERCISE
GUIDANCE ON
DECISION-MAKING
AND
COMMUNICATION
ADDRESSES
OPTION
OF NO
SCREENING
ADDRESSES
WHEN TO
STOP
SCREENING
Dolan & Frisina 200236 Analytic hierarchy
process
Structured interviews,
feasibility testing
Yes Yes Yes Yes Yes No
Zapka 200437 PRECEDE/PROCEED
model, Social
Cognitive Theory
Literature review Yes Yes No No No No
Jerant 200738 Transtheoretical model Personally tailored feedback messages Yes Yes Yes No No No
Myers 200739 Preventive health
model
Tailored messages based on
baseline survey findings
Yes Yes Yes No No No
Ruffin 200740 Elaboration likelihood
model
Developed empirically from 10 focus
groups and 30 patient interviews
Yes Yes Yes Yes No No
Griffith 200841 Transtheoretical model Previous DA, literature review,
usability testing
Yes Yes No Yes No No
Griffith 200842 Transtheoretical model Previous DA, literature review,
focus groups,
expert/patient review
Yes Yes No Yes Yes No
Katsumura 200843 Analytic hierarchy
process
Construction of decision
model
Yes Yes Yes No No No
Lewis 200844 None: DA standard Literature review, patient focus
groups, patient and expert review
Yes Yes No Yes No No
Trevena 200845 Theory of Planned
Behavior
Incorporated research-derived
expert and lay beliefs
Yes Yes Yes Yes No No
Makoul 200946 Extended parallel
process model
Patient interviews and focus groups,
usability testing
Yes Yes No Yes No No
Manne 200947 Health Belief Model,
transtheoretical
model, dual-process
theory
Construction of tailored messages Yes Yes No No No No
Lewis 201048 Ottawa Decision
Support Framework
Literature review, patient interviews,
cognitive testing
Yes Yes Yes No Yes No
Smith 201049 None Specific design for adults with low
literacy skills using plain language
and basic design, focus groups
Yes Yes Yes Yes Yes No
Miller 201150 Transtheoretical model Previous DA, literature review,
usability testing
Yes Yes No Yes No No
Pignone 201151 Transtheoretical model Previous DA, literature review,
usability testing
Yes Yes No Yes No No
Schroy 201152 Ottawa Decision
Support Framework
Literature review, existing DA review,
expert opinion,
focus groups, usability testing
Yes Yes Yes Yes No No
Steckelberg 201153 United Kingdom
Medical Research
Council framework
for complex
intervention
Literature review, focus groups,
expert review
Yes Yes No No Yes No
Vernon 201154 Transtheoretical model Intervention mapping, incorporating
theory and empiric evidence
Yes Yes Yes No No No
Prostate cancer screening (n¼29)
Flood 199655 None Literature review, patient focus
groups, patient and expert review
Yes Yes No Yes Yes No
Wolf 199656 and Wolf &
Schorling 199857
None Physician panel review, pilot testing Yes Yes No No Yes Yes
Myers 199958 Preventive health model Tailored messages based on baseline
survey findings
Yes Yes Yes Yes Yes No
Schapira & VanRuiswyk 200059 Health Belief Model Focus groups Yes Yes No No Yes No
Frosch 200160 None Literature review, patient focus
groups, patient and expert review
Yes Yes No Yes Yes No
Wilt 200161 None Expert review, content validity check,
readability pretesting
Yes Yes No No Yes No
Volk 199962 and Volk 200363 None Literature review, patient focus
groups, patient and expert review
Yes Yes No Yes Yes No
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TABLE 2. (Continued)
STUDYa
THEORETICAL
FRAMEWORK
DESCRIPTION OF
DEVELOPMENT
PROVISION OF
INFORMATION
RISKS AND
BENEFITS
VALUES
CLARIFICATION
EXERCISE
GUIDANCE ON
DECISION-MAKING
AND
COMMUNICATION
ADDRESSES
OPTION
OF NO
SCREENING
ADDRESSES
WHEN TO
STOP
SCREENING
Frosch 200364 None Conversion of a video DA (Frosch
200160) to Web-based DA
Yes Yes No Yes Yes No
Gattellari & Ward 200365 None Literature review, pilot testing Yes Yes Yes Yes Yes No
Ruthman & Ferrans 200466 None Literature review, patient
focus groups,
patient and expert review
Yes Yes No Yes Yes No
Sheridan 200467 None Literature review,
cognitive interviewing
and feedback
Yes Yes No No Yes No
Gattellari & Ward 200568 None Literature review, pilot testing Yes Yes Yes Yes Yes No
Myers 200569 Preventive health
model
Tailored messages based on
baseline survey findings
Yes Yes Yes Yes Yes No
Partin 200470 and Partin 200671 Social Cognitive Theory Literature review, patient
focus groups,
patient and expert review
Yes Yes No Yes Yes No
Watson 200672 None Expert review, field testing Yes Yes No Yes Yes No
Kripalani 200773 None Multidisciplinary team design,
pilot testing
Yes Yes No Yes Yes No
Krist 200774 None Expert review Yes Yes No No No No
Ellison 200875 None Based on Cochrane Review
definition of DA
Yes Yes No No Yes No
Ilic 200876 None NA Yes Yes No No Yes No
Stephens 200877 Prostate cancer
screening decisional
conflict model
Created by the Centers for Disease
Control and Prevention
Yes Yes No Yes Yes No
Volk 200878 None Integration of didactic soap opera
episodes with interactive
learning modules
Yes Yes Yes No Yes No
Weinrich 200879 Social learning theory Previous research findings,
community feedback
Yes Yes No Yes Yes No
Frosch 200880 and
Bhatnagar 200981
Chronic disease model Literature review, health care
professional feedback,
patient usability testing
Yes Yes Yes No Yes No
Allen 200982 Ottawa Decision
Support Framework
Expert opinion and published
research findings
Yes Yes Yes Yes Yes No
Allen 201083 Ottawa Decision
Support Framework
Expert opinion,
International Patient
Decision Aid Standards,
focus groups,
usability testing
Yes Yes Yes Yes Yes No
Joseph-Williams 201084 None Expert review, field testing Yes Yes Yes Yes Yes No
Rubel 201085 None Created by the Centers
for Disease
Control and Prevention
Yes Yes No No Yes No
van Vugt 201086 None Based on screening results of
6288 men
Yes Yes No No Yes No
Capik & Gozum 201287 Health Belief Model Literature review Yes No No Yes No No
Multiple cancer screening (n¼3)
Frosch 200888 None Literature review, patient focus groups,
patient and expert review
Yes Yes No Yes Yes (for
prostate cancer
screening)
No
Brackett 201089 None Literature review, patient
focus groups,
patient and expert review
Yes Yes No Yes Yes (for
prostate cancer
screening)
No
Krist 201290 None Efficacy, adoption and
dissemination trials
Yes Yes No Yes Yes (for
prostate cancer
screening)
No
NA indicates not addressed; PRECEDE/PROCEED, Predisposing, Reinforcing, and Enabling Constructs in Educational Diagnosis and Evaluation/Policy,
Regulatory, and Organizational Constructs in Educational and Environmental Development; DA, decision aid.
aListed in ascending order by the year of publication for each cancer.
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Others provided a list of questions to ask the clinician17,49,84;
some of these provided a list customized to the specific
patient.22,31,82 Other studies attempted to facilitate communi-
cation through practice-based interventions, such as having
the patient use the decision aid immediately before or during
genetic counseling30-32 or providing color codes in the chart
to let the clinicians know of the patient’s readiness for
colorectal cancer screening.34,41,50,51 In all, 43 of 73 decision
aids, including all 3 decision aids on multiple cancer
screening,88-90 provided the guidance on communicating
with clinicians. Neither of the 2 decision aids on cervical
cancer screening did so.12,13
Regarding provision of a ‘‘no screening’’ option, all
decision aids involving breast cancer genetic testing24-33
and all but 2 decision aids involving prostate
cancer screening (including those targeting multiple
cancers)55-73,75-86,88-90 provided such an option. This is
understandable since the choice in these cases is to undergo
the screening test or not. This option was also available
in 4 of 9 breast cancer mammography screening18-21,23
and 6 of 21 colorectal cancer screening decision
aids.35,36,42,48,49,53 Neither of the 2 cervical cancer
screening decision aids provided it.12,13 Of all the decision
aids, only one on mammography screening21 and one on
prostate cancer screening56,57 dealt with the question of
when to stop screening.
Patient Outcomes Assessed for the Decision Aids
Knowledge was assessed in a majority of the decision aids
(52 of 73 decision aids) (Table 3).12-90 Twelve decision aids
had no effect on knowledge.15,20,29,38,41,42,47,64,70,71,76,78,87
Attitude was assessed in 35 of 73 decision aids. There was
no impact on attitude in 4 breast cancer mammography
decision aids.15,18-20,23 Of the 7 breast cancer genetic
testing studies, one showed an increase26 and 2 showed a
decrease in perceived personal risk,24,27,28 one showed a
decrease in positive belief,33 and one showed a decrease in
worry.30 The remaining 2 demonstrated no difference.31,32
One decision aid on cervical cancer screening showed
decreased perception of procedural and cognitive barriers
and increased perceived benefit of the Papanicolaou test.13
Of the 8 colorectal cancer screening decision aids for which
attitude was measured,38,42,43,45,47,49,53,54 there was little
impact. Studies including a ‘‘no screening’’ option resulted
in less clarity concerning perceived benefits42 and a less
positive attitude overall toward colorectal cancer screening.49
The 14 prostate cancer screening decision aids in which the
attitude was measured, all but one of which contained a ‘‘no
screening’’ option, showed overall a more negative attitude
toward prostate cancer screening.59-61,65,68,72,76,77,80-82,84-87
Subjective norm, or perceived social pressure to engage or
not to engage in a behavior, was addressed in just 5 of 73
decision aids.31,32,47,54,88 All but one of them (subjective
norm was found to decrease with one decision aid on
multiple cancer screenings88) showed no effect. Self-efficacy
was addressed in 10 of 73 decision aids. It was increased in
5 decision aids,13,38,54,65,82 decreased in 2,60,88 and not
different in 3 decision aids.45,65,83
Preference clarification was assessed in 31 of 73 decision
aids.16,21,23,31-33,36,40-43,45,48-50,52,53,55,60,61,64,65,68,74,76-78,80-84
In 19 of these, preference clarification was assessed
through decreased decisional conflict, greater values clarity
(eg, a subscale of the decisional conflict scale), or greater
informed choice (a combination of knowledge, values
clarity, and intent).21,23,31,32,36,41,42,45,48,49,53,74-84
Intention was measured in 40 of 73 decision aids.
Nine decision aids led to an increased intention to get
screened; 7 of these concerned colorectal cancer
screening,34,38,46,48,50,52,54 and one each dealt with cervical
cancer screening13 and prostate cancer screening.86 A
decreased intention to undergo screening was noted in 13
decision aids: 8 of these dealt with prostate cancer
screening,55-57,60,62,63,66,70,71,80,81,84; 2 with breast cancer
genetic testing29,33; and one each concerned mammographic
screening,23 cervical cancer screening,12 and multiple cancer
screening.88 No difference in intention was noted in 18
decision aids.21,24-28,35,41,42,45,47,65,67,68,72,76,82,83,87
Screening behavior was assessed in 36 of 73 decision
aids. Thirteen decision aids led to an increase in screening
(7 colorectal cancer screening decision aids,34,39,40,44,47,50,51
3 prostate cancer screening decision aids,58,73,87 2
mammography decision aids,14,17 and one cervical cancer
screening decision aid13), while 5 decision aids led to a
decrease (3 prostate cancer screening,55,62,63,84 one breast
cancer genetic testing,30 and one colorectal cancer
screening decision aid49). Eighteen decision aids showed
no difference in screening.
Patient/Clinician and Practice Outcomes
Assessed for the Decision Aid
Many of the studies on decision aids did not address any of
the issues related to shared decision-making, concordance,
postvisit factors, incorporation into practice, impact of the
decision aid, and cost analysis. Eighteen of 73 decision aids
were assessed for their effect on shared decision-making. No
trend toward an increased degree of shared decision-making
was noted in these 18 studies. All studies used patient self-
report and did not use observational measures, such as audio-
recorded data, to assess shared decision-making. Of note,
none of the decision aids onmammography or cervical cancer
screening addressed shared decision-making as a measure.12-
23 Concordance, or whether the patient and clinician agreed
on a particular cancer screening test option, was addressed in
just 5 of 73 decision aids.31,32,40,52,68 It was high in the 2
decision aids on breast cancer genetic testing,31,32 but only
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TABLE 3. Patient Outcomes Assessed for the Decision Aids
STUDYa KNOWLEDGE ATTITUDE
SUBJECTIVE
NORM SELF-EFFICACY
PREFERENCE
CLARIFICATION INTENTION
SCREENING
BEHAVIOR
Breast cancer mammography screening (n¼9)
Kadison 199814 NA NA NA NA NA NA Self-report: increased BSE
and CBE, but MMG not
increased
Street 199815 No difference No difference in personal
importance or anxiety
NA NA NA NA NA
Lawrence 200016 NA NA NA NA Less preference for MMG,
weaker feeling toward
their own decision
regarding MMG
NA NA
Valdez 200117 NA NA NA NA NA NA Self-report: 51% had
completed or
scheduled MMG
Rimer 200118 and
Rimer 200219
Increased for tailored
print and telephone
counseling vs usual
care; not increased
for tailored print vs
usual care
Increased risk perception NA NA NA NA Self-report: no difference
Lewis 200320 No difference No change or difference in
perception of benefits and
harms
NA NA NA NA NA
Mathieu 200721 Increased NA NA NA Greater values for clarity
and informed choice
No difference Self-report: no difference
Vernon 200822 NA NA NA NA NA NA Self-report: no difference
Mathieu 201023 Increased No difference in perceived
benefits and harms or
anxiety
NA NA No difference in
informed choice
Decreased NA
Breast cancer genetic testing (n¼9)
Lerman 199724 Increased Decreased perceived personal
risk; increased perceived
limitations; no difference
in perceived benefits
NA NA NA No difference NA
Green 200125 Increased NA NA NA NA No difference NA
Schwartz 200126 Increased No difference in perceived
benefits; increased
perceived risk
NA NA NA No difference NA
Green 200427 and
Green 200528
Increased in low-risk
group; no difference
in high-risk group
Greater decrease in absolute
risk perception in low-risk
group; no difference in
high-risk group; no
difference in decrease in
relative risk perception;
greater decrease
in anxiety
NA NA NA No difference Self-report: no difference
Miller 200529 No difference NA NA NA NA Decreased in
average-risk
group, increased
in high-risk group
NA
Wang 200530 Increased Worry declined NA NA NA NA Chart audit: decreased
Wakefield 200831 Increased No difference in distress
(eg, intrusive and
avoidant thoughts,
anxiety, depression)
No difference
in perceived
family
involvement
in decision-
making
NA No difference in Decisional
Conflict Scale except for
Informed subscale (more
informed); no difference in
informed choice or
decisional regret
NA Self-report: no difference
Wakefield 200832 Increased No difference in distress
(eg, intrusive and avoidant
thoughts, anxiety,
depression)
No difference in
perceived family
involvement in
decision-making
NA No difference in Decisional
Conflict Scale except for
Informed subscale (more
informed) and Clear Values
subscale (clearer values);
no difference in informed
choice or decisional regret
NA Self-report: no difference
Gray 200933 NA Decrease in positive beliefs;
no difference in trust in
Internet testing or belief that
Internet testing is wise
NA NA Increased preference for
clinic testing rather than
direct-to-consumer testing
Decreased NA
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TABLE 3. (Continued)
STUDYa KNOWLEDGE ATTITUDE
SUBJECTIVE
NORM SELF-EFFICACY
PREFERENCE
CLARIFICATION INTENTION
SCREENING
BEHAVIOR
Cervical cancer screening (n¼2)
Adab 200312 NA NA NA NA NA Decreased NA
Park 200513 Increased Decreased perception of
procedural barriers and
cognitive barriers; increased
perceived benefit of Pap
test; no difference in
perceived susceptibility
and seriousness
NA Increased NA Increased Self-report: increased
Colorectal cancer screening (n¼21)
Pignone 200034 NA NA NA NA NA Increased Chart review: screening
ordering and completion
increased
Wolf & Schorling
200035
Increased NA NA NA NA No difference NA
Dolan & Frisina
200236
NA NA NA NA Decisional conflict
decreased
NA Chart review: no difference
Zapka 200437 NA NA NA NA NA NA Self-report: no difference
Jerant 200738 No difference No difference in
perceived benefits
and barriers
NA Increased NA Increased NA
Myers 200739 NA NA NA NA NA NA Review of chart, billing,
laboratory database:
increased
Ruffin 200740 NA NA NA NA Increased NA Self-report: increased
Griffith 200841 No difference NA NA NA No difference in decisional
conlict and satisfaction
No difference NA
Griffith 200842 No difference Less clarity regarding
benefits and downsides
with DA that included a
‘‘no screen’’ option
NA NA Less clarity concerning help
in making a decision with
DA that included a
‘‘no screen’’ option
No difference NA
Katsumura 200843 NA Higher priority to
‘‘avoiding disadvantage’’
in information + risk group
NA NA Less preference for COL NA NA
Lewis 200844 NA NA NA NA NA NA Chart review: increased
Trevena 200845 Increased No difference in
anxiety
NA No difference
in perceived
behavioral
control
Increase in decisions that
were informed and had
clear values
No difference Self-report: no difference
Makoul 200946 Increased NA NA NA NA Increased NA
Manne 200947 Not a mediator Not mediators: perceived
risk, severity, preventability
Not mediators:
physician and
family support
NA NA Partial mediator:
decisional balance
Self-report with clinician
confirmation: increased
Lewis 201048 Increased NA NA NA Decisional conflict decreased Increased NA
Smith 201049 Increased Less positive; no difference
in worry about CRC
NA NA Increased informed choice;
decreased decisional
conflict; no difference in
decisional satisfaction or
confidence
NA Laboratory database:
decreased
Miller 201150 NA NA NA NA Report of test preference
increased
Increased Chart review: screening
ordering and completion
increased
Pignone 201151 NA NA NA NA NA NA Self-report: increased
Schroy 201152 Increased NA NA NA No difference between
2 DA groups
Increased NA
Steckelberg 201153 Increased Less positive NA NA Increased informed choice NA Self-report: no difference
Vernon 201154 Increased Increased pros; decreased
cons; no difference in worry
No difference
in social
influence
Increased NA Increased Self-report: no difference
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TABLE 3. (Continued)
STUDYa KNOWLEDGE ATTITUDE
SUBJECTIVE
NORM SELF-EFFICACY
PREFERENCE
CLARIFICATION INTENTION
SCREENING
BEHAVIOR
Prostate cancer screening (n¼29)
Flood 199655 Increased NA NA NA Greater preference for
conservative treatment
Decreased Chart review: decreased
Wolf 199656 and
Wolf & Schorling
199857
NA NA NA NA NA Decreased NA
Myers 199958 NA NA NA NA NA NA Review of chart and billing
data: increased screening
adherence
Schapira &
Van Ruiswyk
200059
Increased Decrease in perceived
benefit
NA NA NA NA Chart review: no difference
Frosch 200160 Increased Less concern about
prostate cancer
NA Less
confidence
about their
decision
Greater preference for
conservative treatment
Decreased NA
Wilt 200161 Increased No difference in
screening belief
NA NA No difference in preference
for conservative treatment
NA Laboratory database:
no difference
Volk 199962 and
Volk 200363
Increased at
2 wk and at 1 y
NA NA NA NA Decreased Self-report: decreased
Frosch 200364 No difference NA NA NA Less preference for
conservative treatment
NA NA
Gattellari & Ward
200365
Increased No difference in worry about
dying of prostate cancer
NA More likely
to report
ability of
making
informed
choice
No difference in overall
decisional uncertainty
No difference NA
Ruthman & Ferrans
200466
Increased NA NA NA NA Less likely to prefer
PSA screening
NA
Sheridan 200467 Increased NA NA NA NA No change in interest
in prostate cancer
screening
NA
Gattellari & Ward
200568
Increased in print DA vs
video DA and leaflet
No difference in worry about
developing prostate cancer
NA No difference
in perceived
ability to make
informed
choice
No difference in overall
decisional uncertainty; less
interest in PSA screening
No difference NA
Myers 200569 NA NA NA NA NA NA Chart review: no difference
Partin 200470 and
Partin 200671
No difference NA NA NA NA Decreased Chart review: no difference
Watson 200672 Increased More negative attitude
toward PSA screening
NA NA NA No difference NA
Kripalani 200773 NA NA NA NA NA NA Chart review: increased
PSA ordering
Krist 200774 Increased NA NA NA No difference in Decisional
Conflict Scale
NA Self-report and clinician
report: no difference
Ellison 200875 Increased NA NA NA NA NA NA
Ilic 200876 No difference No difference in anxiety NA NA No difference in decisional
conflict
No difference NA
Stephens 200877 Increased Increased risk perception NA NA Feeling more informed, to
have clearer values,
and to make more
effective decision
NA NA
Volk 200878 No difference NA NA NA Decreased decisional conflict NA NA
Weinrich 200879 Increased NA NA NA NA NA Chart review: no difference
Frosch 200880 and
Bhatnagar 200981
Increased for DA but not
chronic disease
trajectory
No difference in concern NA NA Greater decrease in
decisional conflict; no
difference in
preference for
conservative treatment
Greater decrease
in DA-only and
chronic disease
trajectory-only
groups to get
PSA screening
but not combined
vs control
NA
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modest in the 2 decision aids concerning colorectal cancer
screening.40,52 The single decision aid study on prostate
cancer screening that addressed concordance noted that it
was affected by the format of the decision aid.68
Only 2 of 73 decision aid studies, both dealing with breast
cancer genetic testing, considered postvisit factors as potential
mediators of screening behavior.31,32 In both studies, a
patient’s sharing of received materials with family was
assessed, with one study noting an increase31 and the other
noting no difference.32 None of the decision aids was assessed
for the effect of media, the referral process for testing,
or other factors that may have also affected screening. Eleven
of 73 decision aids were also assessed for incorporation
into practice: 5 on breast cancer genetic testing,25,29-32 4 on
colorectal cancer screening,34,41,50,51 and 2 on multiple cancer
screening.89,90 The studies generally attempted to link a
clinician visit with the decision aid through timing30 or
modifications to the patient’s chart.31,41,50 Four studies
specifically dealt with how to incorporate the decision aid
into usual practice.32,51,89,90 Only 4 of 73 decision aids were
evaluated for their cost of administration,22,44,54,70,71 which
varied considerably: $2 per decision aid intervention
administered for prostate cancer screening,70,71 $53 per
participant for colorectal cancer screening,54 $94 per
additional patient screened for colorectal cancer,44 or $1116
or more per additional patient screened for breast cancer.22
Discussion
Only 73 decision aids were found to have published data
using our search strategies. This is a rather modest number
given the many recommendations to use such tools.91,92
Most decision aids were evaluated with a sound research
design, such as randomized controlled, 2 2 factorial, and
Solomon 4-group designs. The use of a theoretical
framework and the description of how the decision aid was
developed were more variable. Our finding that just 41 of 73
decision aids (56%) used a theoretical framework is better
than the findings from the review by Durand et al, in which
17 of 50 studies (34%) were shown to have used a theoretical
framework in the development of decision aids for screening
and treatment.93 However, the difference is likely due to the
inclusion of other diseases and treatments in their review.
When the studies in the review by Durand et al are limited
TABLE 3. (Continued)
STUDYa KNOWLEDGE ATTITUDE
SUBJECTIVE
NORM SELF-EFFICACY
PREFERENCE
CLARIFICATION INTENTION
SCREENING
BEHAVIOR
Allen 200982 Increased No difference in risk
perception
NA Increased Decreased decisional conflict No change in
decisional stage
NA
Allen 201083 Increased NA NA No
difference
No difference in decisional
conflict; no change in
decisional consistency
(match between values and
preference for screening)
Increased decisional
stage; no change
in desire for
screening
NA
Joseph-Williams
201084
Increased More negative attitude
toward PSA screening;
no difference in anxiety
NA NA Decreased decisional conflict Decreased Chart review: decreased
Rubel 201085 Increased No difference in positive or
negative schema; no
difference
in risk perception
NA NA NA NA NA
van Vugt 201086 Increased Decreased in perceived risk;
more negative attitude
toward PSA test
NA NA NA Increased NA
Capik & Gozum
201287
No difference Increased susceptibility;
decreased barrier; no
change in benefit
or seriousness
NA NA NA No change Self-report: increased
Multiple cancer screening (n¼3)
Frosch 200888 Increased No difference Decreased Decreased NA Decreased NA
Brackett 201089 NA NA NA NA NA NA NA
Krist 201290 NA NA NA NA NA NA Self-report: no difference in
individual cancer screenings;
increased for overall
delivery of preventive
services
NA, not addressed; BSE, breast self-examination; CBE, clinical breast examination; MMG, mammography; Pap, Papanicolaou; DA, decision aid; COL, colono-
scopy; CRC, colorectal cancer; PSA, prostate-specific antigen.
aListed in ascending order by the year of publication for each cancer.
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to decision aids on cancer screening, 8 of 15 studies (53%)
used a theoretical framework, a figure similar to ours.
Having a theoretical framework is important to determine
how and why a particular decision aid is effective, since it is
from this framework that the measurable outcomes are
derived. The presence of a framework, however, did not
necessarily mean that the development of the decision aid
was well described. In particular, fewer than one-third of
the studies contained enough information for the reviewers
to be able to determine that a formative approach had been
adopted.
The reviewed decision aids uniformly provided
information about the cancer and screening tests and the
benefits and risks of each screening option. In contrast, just
over one-third of the decision aids provided explicit values
clarification exercises. Values clarification may be explicit in
that patient actions are required through an exercise, such as
writing down pros and cons, answering surveys to create
tailored messages, and an analytical hierarchy process.
It could also be implicit, such as when comparing the options
in a table. It is currently unclear whether the explicit method
is superior to the implicit method, although there is emerging
evidence that the former may be better.94 With regard to
guidance on making decisions and communicating with the
clinician, only a few decision aids were found to provide
recommendations that were tailored to the patient. This may
be better provided as part of a practice-based intervention, in
which the decision aid is just one of the interventions, rather
than attempting to put everything into a stand-alone tool.90
Other than the decision aids on breast cancer genetic
testing and prostate cancer screening, in which the decision in
question is whether to be screened, few studies provided the
option of ‘‘no screening.’’ For the established decision aids on
cancer screening to be effective (eg, cervical cancer screening,
colorectal cancer screening), the issue of whether to include
the option of no testing may be a delicate balance between
patient autonomy and beneficence.95 Interestingly, of the 6
colorectal cancer screening decision aids in which this option
was included, only one showed a clear decrease in screening
uptake.49 This may have occurred because the decision aid in
question provided a choice of getting a stool blood test versus
not getting one, whereas in the other 5 studies, the ‘‘no
screening’’ option was listed along with 2 or more screening
options. Thus, the study by Smith et al49 is similar to the
studies of decision aids on breast cancer genetic testing and
prostate cancer screening, which have been shown to decrease
the test uptake. It is of interest to note that the decision aid
that specifically addressed how the inclusion of a ‘‘no
screening’’ option along with multiple screening options
for colorectal cancer affected patient intent showed no
difference, but also indicated that the patients presented with
a ‘‘no screening’’ option felt less clarity in making a decision.42
Few studies included information on when to stop
screening. For breast cancer genetic testing, this is
understandable, since it is a one-time test. For others,
recommendations concerning at what age to stop screening
did not become available until the recent guidelines. In
addition, since most studies focused on a single decision-
making event and not multiple decisions over time, and
typically had a cap on the maximum age for inclusion, the
issue may not have been relevant. From the perspective of
incorporating a decision aid into daily practice, it may be
more feasible to have a separate discussion on when to stop
screening prompted through a clinician reminder system.96
Other than knowledge, there was little consistency in
the patient attributes measured as outcomes in the studies.
The attributes in the Health Belief Model (eg, perceived
benefit, perceived risk) were used most frequently when
assessing the positive or negative attitudes toward
screening. Subjective norm and self-efficacy were rarely
measured. These measures would be important in
determining the contribution of the decision aids to the
decision autonomy of the patients after their use. For
example, patients who perceive greater social pressure
(either through their family, peers, or clinician) may still be
affected by others’ advice after using the decision aid.
Preference clarification was most commonly assessed by
the Decisional Conflict Scale.97 This scale includes
subscales of ‘‘Informed’’ and ‘‘Values Clarity,’’ which may
be particularly relevant when measuring the effects of
decision aids. Some studies have adopted an informed
choice measurement, which is believed to be a better
measure of decision quality and combines the scores of
knowledge, values clarity, and intent or behavior.98 This
measurement may be increasingly adopted in the future
studies on decision aids.
Just approximately one-half of the studies actually
measured screening uptake as an outcome. Of these,
greater than one-half were by patient self-report after a
variable period of time. This may be problematic, since
patients tend to overreport screening behavior.99,100 Other
studies used patient intention rather than screening uptake
as the final outcome, which has an even lower correlation
with actual behavior than self-report.101 Of note, 10 of 73
decision aids had neither intention nor behavior as their
outcome.15,16,20,43,64,75,77,78,85,89 There is little justification
not to measure one or both of these outcomes at this time.
Few studies have actually addressed patient/clinician
communication subsequent to use of a decision aid. Since
the decision aids are purported to improve shared decision-
making, it is surprising that there are few objective data
to support such claims.1,102 The studies that did measure
some component of shared decision-making based their
measurements on patient self-report. Unfortunately,
they are not considered to be sufficiently objective
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measures compared with third-observer instruments such
as the OPTION measurement tool, Decision Support
Assessment Tool, or the Informed and Shared Decision
Making instrument.103-107 The use of these measures
would require recording of the patient/clinician encounter,
which would also make them available for qualitative and
mixed-methods analyses, thereby enriching the findings.
Intriguing questions that may be answered through these
processes include: How is patient/physician communication
affected by the use of decision aids? Is sharing decision-
making between the patient and physician always positively
impacted by decision aids? Are there instances in which
patient activation by decision aids may be deleterious (eg,
patient strongly inclined to use stool blood test for
colorectal cancer screening but the physician strongly
recommends colonoscopy; frustrated, the patient decides
not to get screened)?
Even rarer than the measurement of shared decision-
making was the measurement of concordance. Since shared
decision-making allows for a decision to be deferred when
an agreement is not met, it would be important to assess
whether the decision aid led to an increase in agreement
between the patient and the clinician. Current cancer
screening literature, particularly that regarding colorectal
cancer screening, reveals a potential negative impact on
shared decision-making as the clinicians increasingly prefer
colonoscopy as the test of choice, to the exclusion of
considering patient preference.108 Thus, whether patients
activated through decision aids could steer the clinicians
toward a more shared decision-making approach and
increased concordance would be an important outcome
measure. Postvisit factors, such as the influence of media
and family and the ease of the referral process for
subsequent testing, were addressed so rarely as to be
inconsequential.
The study settings and populations in which the decision
aids were used were sufficiently variable. Thus, these
decision aids would likely lead to similar results in other
settings. More problematic was that the decision aids
tended to be stand-alone and not integrated into the daily
practice routine. This would likely limit their practical use.
When intention-to-treat analysis is adopted, many studies
show a very small to negligible effect by the decision aids,
due to the low usage by patients. In addition, studies have
shown that although clinicians like the concept of decision
aids, they actually rarely use them in settings that are
conducive to shared decision-making and where publicly
accessible decision aids are available.109 Unless the decision
aids incorporate risk assessment and tailor their values
clarification exercises accordingly (eg, moving from
multiple options in average-risk patients to recommending
colonoscopy in patients at increased risk in colorectal
cancer screening), or a reminder system exists that
could link patients to decision aids based on their
profile, clinicians may perceive the decision aids to be too
cumbersome. These barriers may not be overcome
unless a more comprehensive, practice-based approach is
adopted.110-113 An excellent example of using a practice-
based approach in a real-world setting is a recent
publication from a large health system in Washington
State. Their organizational effort to implement decision
aids for patients facing hip and knee arthritis and joint
replacement surgery was associated with 26% fewer hip
replacement surgeries, 38% fewer knee replacements, and
12% to 21% lower costs over 6 months.114 Currently, only
one study has attempted an improvement in cancer
screening through practice-wide intervention, including the
use of decision aids.90
What Can Practicing Physicians Do?
First, physicians need to accept that cancer screening has
elements that are sensitive to patient preferences and choice.
Second, it would be helpful for physicians to know how to
access useful decision aids. An example is the repository of
decision aids available from the Ottawa Hospital Research
Institute in Ontario, Canada. Their Web site
(decisionaid.ohri.ca/AZlist.html) contains links to high-quality
decision aids in various topics, including screening for all of the
cancers discussed in this review. Third, many organizations
offer free information to patients in a way that may still provide
them with desired information on how the cancer screening
tests work and their risks and benefits. An example would
be the American Cancer Society Web site (cancer.org), which
provides the latest information on screening for breast, cervical,
colorectal, and prostate cancers, among others. The barrier is
how and when one uses these existing tools in the course
of a busy day. It will likely be either before or after the
physician visit, thus unloading time and effort from the
visit itself. Fourth, the state-of-the-art interactive decision
aid may not be feasible in a real-world practice setting at
this time. This reality may be reflected in the fact that
many of even the more recent studies use print rather
than Web-based decision aids.
With the increasing use of electronic medical records
linked to patient portals, as well as advances in mobile
telephones and their applications, decision aids that
are accessible and easily understandable may become more
available in a timely manner to patients in the near future.
The features used to evaluate the studies in this review
would serve as an excellent checklist for physicians to use
when examining such tools.
Limitations
First, despite an exhaustive attempt to identify all published
English language studies on this topic, due to the
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differences in current indexing practices in and among the
electronic databases, we cannot ensure that we have
examined all of the published English language works in
this subject area. Some studies were published in abstract
form only and could not be included due to a lack of detail.
Second, there are likely to be unpublished studies relevant to
this area. It is unknown if the results of these studies would
sway the assessment given that most unpublished studies
contain negative findings. Third, the published data lacked
significant details regarding how the decision aids work. We
searched for relevant articles on their development and accessed
the original tools if available, but this was possible in only a
minority of the cases. It may be that some decision aids actually
possess the features that we had concluded were lacking.
Fourth, the published data lacked detailed information on how
the decision aids were developed and how the outcomes
measures were determined. Because of this, we did not rigidly
apply the International Patient Decision Aids Standards
(IPDAS) criteria to the decision aids. Of note, IPDAS is an
internationally recognized scoring system of decision aid
quality.115 It measures the quality of the decision aids in 10
dimensions, including information provided, description of
probabilities, and availability of decision guidance. It is
increasingly influential in determining how decision aids
should be developed. Finally, our approach to evaluating
these studies highlights the vast array of complex data that
need to be gathered and analyzed to adequately address the
topics that were considered. For many investigators,
collecting such a quantity and diversity of data may have
been beyond their funding, resources, or skill set. It also may
not be well reviewed at study review sections that place a
priority on focused research questions. In addition, many
investigators’ research teams lack expertise in certain areas
not addressed. The collection of adequate data also may
create too much of a burden on the study participants, which
would limit accrual and follow-up. Thus, the ideal scenario
would be a series of studies expanding the focus and further
refining the intervention, which we did not find.
Unique Features of Our Review
Many high-quality reviews are available on decision
aids.116,117 Our review is unique because it focused on
cancer screening and measurable outcomes based on a
theoretical framework. In particular, this review
elucidated that few decision aids on cancer screening
actually evaluated their effect on a patient’s entire
decision-making process, including shared decision-
making and reaching concordance with their clinician.
Our review indicated areas in which further research is
needed, as we detail below. Among the most important
would be having a theoretical framework so that
appropriate outcomes are measured, an objective
assessment of shared decision-making, and attention to
applicability in other settings.
Suggestions for Future Research
1) A strong theoretical framework should support the de-
cision aid and guide its development as well as mea-
surement outcomes. There should be a clear
correlation between the theoretical framework and the
measured outcomes.
2) There should be more studies that critically compare
explicit versus implicit values clarification.
3) An objective measure of screening uptake (eg, paper
chart review, extraction of electronic health record
data) should be adopted to assess the effectiveness of
the decision aid.
4) Shared decision-making between the patient and the
clinician should be recorded and objectively measured
by validated tools.
5) Other potential mediators that temporally occur after
the patient’s decision aid use, such as media and
family influence, should be considered.
6) How decision aids would fare as a meaningful part
of primary care practice should be assessed through
their better integration into practice and a broader,
practice-based approach to measure their
effectiveness.
7) To address applicability in real-world settings, studies
should continue to be performed in heterogeneous
community practice settings, using practice-based
research networks.
8) Long-term effectiveness and viability should
be addressed, including the effect on repeated screening
and cost-effectiveness and cost-benefit analyses.
9) With the advent of more options in breast and
cervical cancer screening and the need for even better
informed and shared decision-making in prostate
cancer screening with the advent of conflicting
guidelines, there are even more opportunities for
decision aids to be useful in the setting of cancer
screening.
Conclusions
Decision aids are here to stay. Although much research
needs to be done to determine what really makes for an
effective decision aid, practical applications are already
occurring. Many decision aids are now available free of
charge. Clinicians are encouraged to explore them, select
those that fit best with their current understanding of the
topic in question, and apply them to their practice
workflow in a creative way. n
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